HPV Vaccine Schedule and Dosing

ACIP makes recommendations based on the best available scientific evidence. Immunogenicity studies show that two doses of HPV vaccine given at least 6 months apart to 9–14-year-olds provided as good or better antibody responses as three doses given to older adolescents or young adults.

Answering parents’ questions: The data we have from current scientific studies show that in children age 9–14 years,  two doses of HPV vaccine given at least 6 months apart were as good or better as three doses. The immune response for older people hasn’t been studied in the same way, so information is not available for that age group. For this reason, older teens and adults should get three doses for best protection.

Yes. In a 2-dose schedule of HPV vaccine, the recommended interval is 6–12 months, and the minimum interval is 5 months between the first and second dose. If the second dose is given earlier than 5 months, a third dose should be given.

Answering parents’ questions: The recommended schedule is two doses given 6 –12 months apart. The minimum amount of time between those doses is 5 months. Because your child received two doses less than 5 months apart, your child should get a third dose.

This person needs one more dose to complete a 2-dose series, which is recommended because the vaccination series was started before their 15^th birthday. In a 2-dose series, the second dose is recommended 6–12 months after the first dose, but there is no upper time limit. In this case, the first dose was given several years ago, so the second dose can be given right away.

Answering parents’ questions: Since your child received the first dose before 15 years of age, they only need one more dose to be fully protected. However, the second dose should be given as soon as possible and not further delayed.

CDC recommends three doses of HPV vaccine (0, 1–2, 6-month schedule) for people ages 9–26 years if they have certain immunocompromising conditions. People whose immune responses might be lower, for example due to HIV infection, cancer, transplantation, autoimmune disease, or taking immunosuppressant medications, should receive three doses to make sure they get the most benefit. However, children with asthma, diabetes, and other conditions that do not suppress immune response to vaccination can receive a 2-dose schedule.

Answering parents’ questions: Even though CDC has recommended just two doses of HPV for kids under 15 years, your child should get three doses because they have a health condition that can weaken the immune system.

Any licensed HPV vaccine can be used to complete the vaccination series with the same recommended schedule and dosing intervals.

If the first dose of any HPV vaccine was given before the 15^th birthday, vaccination should be completed according to a 2-dose schedule. In a 2-dose series, the second dose is recommended 6–12 months after the first dose (0, 6–12-month schedule).

If the first dose of any HPV vaccine was given on or after the 15^th birthday, vaccination should be completed according to a 3-dose schedule. In a 3-dose series, the second dose is recommended 1–2 months after the first dose, and the third dose is recommended 6 months after the first dose (0, 1–2, 6-month schedule).

If the vaccination schedule is interrupted, vaccine doses do not need to be repeated.

Answering parents’ questions: A 9-valent HPV vaccine that protects against infections with nine types of the virus has been available in the United States since 2016. If your child got their first dose of HPV vaccine before 2016, they may have received a 2-valent or 4-valent vaccine. Regardless of which vaccine they received previously, they should complete the series with the currently available HPV vaccine. They will not need to restart the series.

HPV vaccination provides the most benefit when given before a person is exposed to any HPV. This is why CDC recommends HPV vaccination at age 11–12 years. HPV vaccination is also recommended through age 26 years for everyone who did not get vaccinated when they were younger.

Vaccination is not recommended for everyone older than age 26 years. In general, HPV vaccination of people in this age range provides minimal benefit because most people have been exposed to HPV already. However, some adults aged 27–45 years who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination.

For adults who are 27–46 years old, clinicians can consider discussing HPV vaccination with people who are most likely to benefit. HPV vaccination does not need to be discussed with most adults over age 26 years. For more details, see Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices | MMWR (cdc.gov).

Answering patients’ questions: Most sexually active adults have been exposed to HPV already, although not necessarily all of the HPV types prevented by vaccination. At any age, having a new sex partner is a risk factor for getting a new HPV infection. People who are already in a long-term, mutually monogamous relationship are not likely to get a new HPV infection.

HPV vaccination prevents new HPV infections but does not treat existing infections or diseases.